NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis $1.13 +0.01 (+0.89%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeuroSense Therapeutics Stock (NASDAQ:NRSN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NRSN alerts:Sign Up Key Stats Today's Range$1.10▼$1.1750-Day Range$1.08▼$2.4552-Week Range$0.68▼$2.60Volume82,625 shsAverage Volume241,944 shsMarket Capitalization$15.45 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company Overview NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. Read More NeuroSense Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreNRSN MarketRank™: NeuroSense Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 614th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeuroSense Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroSense Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about NeuroSense Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroSense Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroSense Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeuroSense Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.25% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently increased by 48.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroSense Therapeutics does not currently pay a dividend.Dividend GrowthNeuroSense Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.25% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently increased by 48.25%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.47 News SentimentNeuroSense Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.04% of the stock of NeuroSense Therapeutics is held by institutions.Read more about NeuroSense Therapeutics' insider trading history. Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRSN Stock News HeadlinesNeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 2.9% - What's Next?August 23, 2025 | americanbankingnews.comNeuroSense Therapeutics Ltd. (NRSN) - Yahoo FinanceAugust 22, 2025 | finance.yahoo.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28 at 2:00 AM | Weiss Ratings (Ad)NeuroSense Therapeutics Announces Annual General Meeting for September 2025August 22, 2025 | msn.comNeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeCAugust 20, 2025 | msn.comNeuroSense Reports Long-Term Safety of PrimeC in ALS StudyAugust 20, 2025 | tipranks.comD. Boral Capital Reaffirms "Buy" Rating for NeuroSense Therapeutics (NASDAQ:NRSN)August 17, 2025 | americanbankingnews.comNeuroSense Provides Business Update and Progress for the First Half of 2025August 1, 2025 | prnewswire.comSee More Headlines NRSN Stock Analysis - Frequently Asked Questions How have NRSN shares performed this year? NeuroSense Therapeutics' stock was trading at $1.20 at the beginning of the year. Since then, NRSN stock has decreased by 5.8% and is now trading at $1.13. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) announced its quarterly earnings data on Monday, April, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.06. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an IPO on Thursday, December 9th 2021. The company issued 2,000,000 shares at a price of $6.00-$7.00 per share. Who are NeuroSense Therapeutics' major shareholders? Top institutional shareholders of NeuroSense Therapeutics include Jane Street Group LLC (0.21%). How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroSense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE). Company Calendar Last Earnings4/07/2025Today8/28/2025Next Earnings (Estimated)9/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRSN CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for NeuroSense Therapeutics$14.00 High Price Target$14.00 Low Price Target$14.00 Potential Upside/Downside+1,133.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.21 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-445.40% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio2.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-28.38Miscellaneous Outstanding Shares13,670,000Free Float9,922,000Market Cap$15.52 million OptionableNot Optionable Beta1.64 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NRSN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.